# Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer

> **NCT02467569** · PHASE1 · TERMINATED · sponsor: **Tianjin Hemay Pharmaceutical Co., Ltd** · enrollment: 10 (actual)

## Conditions studied

- Neoplasms，Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Hemay020

## Key facts

- **NCT ID:** NCT02467569
- **Lead sponsor:** Tianjin Hemay Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-03
- **Primary completion:** 2017-12-31
- **Final completion:** 2017-12-31
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02467569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02467569, "Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02467569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*